Stock Scorecard
Stock Summary for X4 Pharmaceuticals Inc (XFOR) - $3.55 as of 5/30/2025 6:09:42 PM EST
Total Score
16 out of 30
Safety Score
43 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for XFOR
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for XFOR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for XFOR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for XFOR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for XFOR (43 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 6 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 10 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for XFOR
Financial Details for XFOR
Company Overview |
|
|---|---|
| Ticker | XFOR |
| Company Name | X4 Pharmaceuticals Inc |
| Country | USA |
| Description | X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back diseases. The company is headquartered in Boston, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 3.55 |
| Price 4 Years Ago | 68.70 |
| Last Day Price Updated | 5/30/2025 6:09:42 PM EST |
| Last Day Volume | 122,159 |
| Average Daily Volume | 564,202 |
| 52-Week High | 33.90 |
| 52-Week Low | 2.67 |
| Last Price to 52 Week Low | 32.96% |
Valuation Measures |
|
| Trailing PE | 1.54 |
| Industry PE | 59.99 |
| Sector PE | 40.42 |
| 5-Year Average PE | 8.52 |
| Free Cash Flow Ratio | 0.51 |
| Industry Free Cash Flow Ratio | 19.17 |
| Sector Free Cash Flow Ratio | 31.66 |
| Current Ratio Most Recent Quarter | 3.70 |
| Total Cash Per Share | 6.95 |
| Book Value Per Share Most Recent Quarter | 3.96 |
| Price to Book Ratio | 0.86 |
| Industry Price to Book Ratio | 18.65 |
| Sector Price to Book Ratio | 29.96 |
| Price to Sales Ratio Twelve Trailing Months | 0.60 |
| Industry Price to Sales Ratio Twelve Trailing Months | 42.37 |
| Sector Price to Sales Ratio Twelve Trailing Months | 40.56 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 5,788,700 |
| Market Capitalization | 20,549,885 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 62.98% |
| Reported EPS 12 Trailing Months | 2.11 |
| Reported EPS Past Year | 0.04 |
| Reported EPS Prior Year | -0.71 |
| Net Income Twelve Trailing Months | 14,598,000 |
| Net Income Past Year | -37,450,000 |
| Net Income Prior Year | -101,167,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | -3.15% |
| Operating Margin Twelve Trailing Months | -32.80% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 40,257,000 |
| Total Cash Past Year | 55,699,000 |
| Total Cash Prior Year | 99,216,000 |
| Net Cash Position Most Recent Quarter | -35,372,000 |
| Net Cash Position Past Year | -19,726,000 |
| Long Term Debt Past Year | 75,425,000 |
| Long Term Debt Prior Year | 54,570,000 |
| Total Debt Most Recent Quarter | 75,629,000 |
| Equity to Debt Ratio Past Year | 0.23 |
| Equity to Debt Ratio Most Recent Quarter | 0.23 |
| Total Stockholder Equity Past Year | 22,149,000 |
| Total Stockholder Equity Prior Year | 51,099,000 |
| Total Stockholder Equity Most Recent Quarter | 22,944,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -112,939,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -19.51 |
| Free Cash Flow Past Year | -131,227,000 |
| Free Cash Flow Prior Year | -96,572,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.71 |
| MACD Signal | -0.90 |
| 20-Day Bollinger Lower Band | -1.03 |
| 20-Day Bollinger Middle Band | 9.29 |
| 20-Day Bollinger Upper Band | 19.61 |
| Beta | 0.73 |
| RSI | 37.27 |
| 50-Day SMA | 15.54 |
| 150-Day SMA | 29.89 |
| 200-Day SMA | 44.60 |
System |
|
| Modified | 5/29/2025 2:22:27 PM EST |